● Recruiting

A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer

Condition: Locally Advanced Rectal Cancer · Sponsor: Chinese PLA General Hospital

PhasePhase 2

Planned participants44

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

In pMMR/MSS locally advanced rectal cancer, can the innovative "chemo-immunotherapy induction + LCRT + chemo-immunotherapy consolidation" approach significantly improve the complete response rate and create opportunities for organ preservation?

This description comes directly from the study's public registry record.

Talk to the study team

Guanghai Dai, MD · +86 13801232381 · 463043539@qq.com

Xiao Wang · +86 13502005172 · 463043539@qq.com

Always discuss trial participation with your own doctor first.

Locations (1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07527026